NVZMF (Novonesis (Novozymes) B) ROCE % : 0.00% (As of Jun. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Novonesis (Novozymes) B ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Novonesis (Novozymes) B's annualized ROCE % for the quarter that ended in Jun. 2024 was 0.00%.

Novonesis (Novozymes) B ROCE % Historical Data

The historical data trend for Novonesis (Novozymes) B's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B ROCE % Chart

Novonesis (Novozymes) B Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

25.71

23.40

21.95

22.49

19.66

Novonesis (Novozymes) B Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial															22.88	15.81	21.47	19.67	-

Novonesis (Novozymes) B ROCE % Calculation

Novonesis (Novozymes) B's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	597.9	/	( ( (3978.441 - 989.954)	+	(4158.496 - 1063.682) )	/ 2 )
	=	597.9	/	( (2988.487	+	3094.814)	/ 2 )
	=	597.9	/	3041.6505
	=	19.66 %

Novonesis (Novozymes) B's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	0	/	( ( (4158.496 - 1063.682)	+	(16417.869 - 1755.221) )	/ 2 )
	=	0	/	( ( 3094.814	+	14662.648 )	/ 2 )
	=	0	/	8878.731
	=	0.00 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

Novonesis (Novozymes) B (OTCPK:NVZMF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Novonesis (Novozymes) B ROCE % Related Terms

Thank you for viewing the detailed overview of Novonesis (Novozymes) B's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Novonesis (Novozymes) B Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (OTCPK:NVZMF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

NVZMY:USA NSISBc:UK 0Q4U:UK NSIS B:Denmark NZM2:Germany

Address

Krogshoejvej 36, Bagsvaerd, DNK, 2880

Website

https://www.novozymes.com

Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.